单次干预人群前列腺癌筛查研究的长期结局
1988年从27,464名男性中随机选取2,400人邀请筛查,1,779人(74%)接受直肠指检、超声和PSA检测,PSA>10 ng/ml或影像异常者行活检。20年后评估显示,参与者总体死亡率低于源人群(IRR 0.93,95%CI 0.86-0.98),非参与者总体死亡率升高(IRR 1.25,95%CI 1.14-1.37),但组间前列腺癌特异性生存无差异,筛查人群前列腺癌发病率持续较高。结论认为该单次筛查干预不降低前列腺癌特异性死亡率,不应作为公共筛查方案。
要点
- 单次PSA+直肠指检+超声筛查未降低前列腺癌特异性死亡率。
- 参与者总体死亡率低于源人群(IRR 0.93),非参与者死亡率升高(IRR 1.25)。
- 筛查人群前列腺癌发病率持续高于源人群,但无生存获益。
核心结论
- 单次PSA、直肠指检和经直肠超声筛查(活检阈值PSA>10 ng/ml)在20年后未降低前列腺癌特异性死亡率,不应考虑用于公共筛查。
- 非参与者全因死亡风险高于源人群。
研究设计与样本
- 1988年从27,464名背景人群中随机选取2,400名男性邀请筛查,1,779人(74%)接受检查。
- 筛查方法为直肠指检、超声和PSA检测,超声或直肠指检可疑或PSA>10 ng/ml时行活检。
- 20年后对亚人群重新评估。
主要发现
- 参与者总体死亡率低于源人群(IRR 0.93,95%CI 0.86-0.98)。
- 非参与者总体死亡率高于源人群(IRR 1.25,95%CI 1.14-1.37)。
- 组间前列腺癌特异性生存无差异。
- 筛查人群前列腺癌发病率在整个随访期间持续高于源人群。
关键数值与推荐
- 活检阈值:PSA>10 ng/ml或超声/直肠指检可疑。
- 筛查年龄:50至75岁男性。
- 干预方式:单次筛查干预。
临床怎么用
- 不建议将单次PSA联合直肠指检和超声筛查作为公共筛查策略。
- 临床决策时应告知单次筛查不降低前列腺癌特异性死亡率。
局限性
- 单次干预试验设计。
- 活检PSA阈值(10 ng/ml)已过时。
- 筛查方法陈旧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the long-term effect of screening for prostate cancer. MATERIALS AND METHODS: In 1988 we randomly selected 2,400 men from a background population of 27,464 men. The 2,400 men were invited to undergo screening, of whom 1,779 (74%) accepted and were examined with digital rectal examination, ultrasound and prostate specific antigen measurement. Biopsy was performed if there were suspicious findings on ultrasound or digital rectal examination, or prostate specific antigen was greater than 10 ng/ml. The subpopulations have now been reassessed after 20 years. RESULTS: Participants had a decreased overall mortality rate compared to the source population (IRR 0.93, 95% CI 0.86-0.98). Nonparticipants had an increased overall mortality rate (IRR 1.25, 95% CI 1.14-1.37). There was no difference between the groups in prostate cancer specific survival. The incidence of prostate cancer remained higher in the screened population throughout followup. CONCLUSIONS: A single screening intervention in men 50 to 75 years old using prostate specific antigen, digital rectal examination and transrectal ultrasound, and a prostate specific antigen cutoff of 10 ng/ml for biopsy carried a significant risk of prostate cancer detection without a concomitant reduction in prostate cancer specific mortality after 20 years. This intervention should not be considered for public screening. Nonparticipants were at greater risk for death of all causes. In addition to being a single intervention trial, the limitations of this study include an outdated prostate specific antigen cutoff for biopsy. Despite the outdated screening method the source population failed to reach the same level of prostate cancer incidence as the screened population even after 20 years.
引用
- Lundgren PO, Kjellman A, Norming U, et al. Long-Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study. J Urol. 2018. PMID: 29408619. doi:10.1016/j.juro.2018.01.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。